Table 3.
KEGG Pathways Enriched in Animal and Human Experimental Lung Injury
| Animal Lung Pathways | Combined FDR | Human BAL Pathways | Combined FDR |
|---|---|---|---|
| hsa04060: Cytokine–cytokine receptor interaction | 0.0004 | hsa04010: MAPK signaling | 1.72E−05 |
| hsa04010: MAPK signaling pathway | 0.0012 | hsa04062: Chemokine signaling | 1.72E−05 |
| hsa05146: Amoebiasis | 0.0013 | hsa04740: Olfactory transduction | 1.72E−05 |
| hsa05152: Tuberculosis | 0.0013 | hsa04932: Nonalcoholic fatty liver disease | 1.72E−05 |
| hsa04062: Chemokine signaling pathway | 0.0013 | hsa05146: Amoebiasis | 1.72E−05 |
| hsa04064: NF-κB signaling pathway | 0.0013 | hsa05152: Tuberculosis | 1.72E−05 |
| hsa05166: HTLV-I infection | 0.0029 | hsa05169: Epstein-Barr virus infection | 1.72E−05 |
| hsa04110: Cell cycle | 0.0029 | hsa04060: Cytokine–cytokine receptor interaction | 2.11E−05 |
| hsa04932: Nonalcoholic fatty liver disease | 0.0036 | hsa04064: NF-κB signaling | 2.11E−05 |
| hsa04115: p53 signaling pathway | 0.0041 | hsa05161: Hepatitis B | 2.11E−05 |
Definition of abbreviations: BAL, bronchoalveolar lavage; FDR, false discovery rate; KEGG, Kyoto Encyclopedia of Genes and Genomes; HTLV-1, human T-cell lymphotropic virus type 1; MAPK, mitogen-activate protein kinase.
The top 10 significant pathways are shown for each condition. Common pathways are in boldface type.